Edgewise Therapeutics Inc. (NASDAQ: EWTX ) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial. Patients received doses ranging from 25 mg to 150 mg . EDG-7500 demonstrated clinically meaningful improvements in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). HCM is a genetic heart condition where the heart muscle thickens, making it harder for the heart to pump blood and potentially leading to complications like heart failure or sudden cardiac death. data-variant="card" data-news-mode="manual" > Read Also: Cytokinetics Wins FDA Nod For Heart Drug Myqorzo The company said the oral cardiac sarcomere modulator improved key measures of heart function, symptoms, and biomarkers without compromising systolic function. Strong Improvements Seen In Obstructive HCM Patients The Part D cohort enrolled 53 patients, including 20 with obstructive HCM (oHCM) and 33 with nonobstructive HCM (nHCM). The 12-week study was designed to help inform a future Phase ... Full story available on Benzinga.com
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
